How many BCL-2 inhibitor clinical trials are currently active?

As of March 2026, there are 184 active BCL-2 inhibitor trials on ClinicalTrials.gov, with 101 actively recruiting. Venetoclax (AbbVie/Roche) dominates with the largest footprint across CLL, AML, and multiple myeloma. BeOne Medicines (formerly BeiGene) is running 4 Phase 3 CELESTIAL studies with sonrotoclax (BGB-11417), directly challenging venetoclax in CLL and MCL.

What is sonrotoclax and how does it compare to venetoclax?

Sonrotoclax (BGB-11417) is BeOne Medicines' next-generation BCL-2 inhibitor. It is reported to have greater BCL-2 binding potency and better tissue distribution than venetoclax, potentially allowing deeper tumor penetration in lymph node-rich diseases like CLL. BeOne is running head-to-head Phase 3 trials comparing sonrotoclax+zanubrutinib to venetoclax-based regimens in CLL (first-line and R/R) and sonrotoclax+zanubrutinib to placebo+zanubrutinib in mantle cell lymphoma. If positive, sonrotoclax would represent the first direct challenge to venetoclax's market position.

What is the standard of care for venetoclax in AML?

Venetoclax plus azacitidine (ven+aza) became the standard of care for newly diagnosed AML patients ineligible for intensive induction chemotherapy following the VIALE-A Phase 3 trial (AbbVie, 2020). Response rates of ~65% (composite CR/CRi) compared to ~28% for azacitidine alone established ven+aza as transformative. The combination is now the backbone on which virtually all new AML combination regimens are built — over 60 active Phase 3 trials test venetoclax-containing regimens in AML or MDS.

What is navitoclax and how is it different from venetoclax?

Navitoclax (ABT-263, AbbVie) is a dual BCL-2/BCL-XL inhibitor, unlike venetoclax which is BCL-2 selective. BCL-XL inhibition was abandoned in early development because thrombocytopenia (platelet destruction) was dose-limiting — platelets depend on BCL-XL for survival. AbbVie is exploring navitoclax in myelofibrosis (TRANSFORM-2, Phase 3) in combination with ruxolitinib, where thrombocytopenia is managed and the broader apoptotic activity may target JAK inhibitor-resistant clones.

How does DataLookout monitor BCL-2 inhibitor competitive intelligence?

DataLookout monitors ClinicalTrials.gov daily for new BCL-2 inhibitor trial registrations and status changes. The ven+aza AML standard is attracting dozens of combination partners, and sonrotoclax's Phase 3 readouts will reshape CLL treatment sequencing. Daily alerts notify pharma BD teams when enrollment opens, competing programs register, or trial status changes.

BCL-2 Inhibitor Clinical Trials — Venetoclax vs Sonrotoclax Pipeline 2026

184

Active BCL-2 Trials

101

Recruiting Now

BeOne CELESTIAL P3s

2026

Data as of March

CELESTIAL Program Update: BeOne Medicines is running four simultaneous Phase 3 trials with sonrotoclax (BGB-11417), including CELESTIAL-RRCLL (vs venetoclax+rituximab in R/R CLL), CELESTIAL-RRMCL (vs placebo+zanubrutinib in MCL), and a first-line CLL trial comparing sonrotoclax+zanubrutinib directly to venetoclax+acalabrutinib. All actively recruiting as of March 2026.

Key Phase 3 Trials: CLL

Trial	Regimen	Sponsor	Comparator	Status
NCT07277231	Sonrotoclax + Zanubrutinib	BeOne Medicines	Venetoclax + Acalabrutinib (1L CLL)	Recruiting Phase 3
NCT06943872 CELESTIAL-RRCLL	Sonrotoclax + Obinu or Rituximab	BeOne Medicines	Venetoclax + Rituximab (R/R CLL)	Recruiting Phase 3
NCT06073821	Sonrotoclax + Zanubrutinib	BeOne Medicines	Venetoclax + Obinutuzumab (1L CLL)	Active Phase 3
NCT05057494	Acalabrutinib + Venetoclax	AstraZeneca	Venetoclax + Obinutuzumab (1L CLL)	Active Phase 3
NCT03462719	Ibrutinib + Venetoclax	Janssen	Chlorambucil + Obinutuzumab (1L CLL)	Active Phase 3
NCT05947851 BELLWAVE-010	Nemtabrutinib + Venetoclax	Merck	Venetoclax + Rituximab (R/R CLL)	Recruiting Phase 3
NCT04965493	Pirtobrutinib + Venetoclax + Rituximab	Loxo/Lilly	Venetoclax + Rituximab (R/R CLL)	Active Phase 3
NCT07321652	Sonrotoclax + Zanubrutinib	Alliance (NCI)	Zanubrutinib alone (1L CLL)	Active Phase 3

Key Phase 3 Trials: AML

Trial	Regimen	Sponsor	Setting	Status
NCT06852222	Bleximenib + Venetoclax + Azacitidine	Janssen	Newly diagnosed AML	Recruiting Phase 3
NCT04628026	Induction chemo + Venetoclax	Univ. of Ulm	Newly diagnosed AML/MDS-EB-2	Recruiting Phase 3
NCT05183035	Venetoclax (pediatric AML)	PedAL BCU	Relapsed pediatric AML	Recruiting Phase 3
NCT04256317 AZTOUND	ASTX030 (oral aza) ± Venetoclax	Taiho Oncology	AML (oral azacitidine formulation)	Recruiting Phase 3

Key Phase 3 Trials: Myelofibrosis and MCL

Trial	Drug	Sponsor	Indication	Status
NCT04468984 TRANSFORM-2	Navitoclax + Ruxolitinib	AbbVie	R/R Myelofibrosis	Active Phase 3
NCT06742996 CELESTIAL-RRMCL	Sonrotoclax + Zanubrutinib	BeOne Medicines	R/R Mantle Cell Lymphoma	Recruiting Phase 3

The Venetoclax Foundation: Standard of Care Dominance

Venetoclax (ABT-199/GDC-0199, co-developed by AbbVie and Roche/Genentech, marketed as Venclexta) has fundamentally changed outcomes in CLL and AML since its FDA approval in 2016. By selectively inhibiting BCL-2 — the master regulator of apoptosis that CLL and AML cells depend on for survival — venetoclax restores the programmed cell death machinery that cancer cells have hijacked.

Its current standard-of-care positions:

CLL/SLL first-line: Venetoclax + obinutuzumab (fixed-duration, 12 months) — VIALE-CLL3/CLL14. High MRD negativity rates (>50%) enabling treatment discontinuation.
CLL/SLL R/R: Venetoclax + rituximab (fixed-duration, 24 months) — MURANO. Alternative to continuous BTK inhibitor therapy.
AML, newly diagnosed unfit: Venetoclax + azacitidine — VIALE-A. Response rate ~65% vs ~28% for azacitidine alone. Now the de facto standard for elderly/unfit AML patients globally.
AML, newly diagnosed unfit (alternative): Venetoclax + low-dose cytarabine — VIALE-C. For patients unable to tolerate azacitidine.

This market position translates into extraordinary commercial durability. With 184 active trials using venetoclax, it has become the oncology equivalent of a platform drug — competitors must design trials against it, not just in parallel.

The Sonrotoclax Challenge: CELESTIAL at Scale

BeOne Medicines (the rebranded BeiGene) is executing the most systematic challenge to venetoclax since the drug's approval. Sonrotoclax (BGB-11417) is designed to be a best-in-class BCL-2 inhibitor with reported 5–10x greater BCL-2 binding potency than venetoclax and improved tissue distribution into lymph nodes — precisely where CLL cells reside.

BeOne's CELESTIAL program spans four Phase 3 trials:

First-line CLL vs venetoclax+obinutuzumab: NCT06073821 (vs the established time-limited standard, sonrotoclax+zanubrutinib)
First-line CLL vs venetoclax+acalabrutinib: NCT07277231 (a direct next-gen BTKi+BCL-2 doublet comparison — highly informative for treatment sequencing)
R/R CLL (CELESTIAL-RRCLL): NCT06943872 (vs venetoclax+rituximab in previously treated patients)
R/R MCL (CELESTIAL-RRMCL): NCT06742996 (sonrotoclax+zanubrutinib vs placebo+zanubrutinib)

The strategic significance: if sonrotoclax achieves deeper or more durable MRD negativity than venetoclax in any of these trials, it would validate next-generation BCL-2 inhibition as a distinct clinical advance — shifting treatment algorithms and opening licensing opportunities for biotech companies with BCL-2 program assets.

BD Intelligence: BeOne's zanubrutinib (Brukinsa) is already approved and growing rapidly in CLL. CELESTIAL leverages this commercial position — if sonrotoclax+zanubrutinib becomes the preferred doublet, BeOne controls both drugs. Monitoring CELESTIAL enrollment pace and interim signals is critical for any CLL/MCL program.

Navitoclax and the BCL-XL Question

Navitoclax (ABT-263) is AbbVie's dual BCL-2/BCL-XL inhibitor that predated venetoclax. BCL-XL inhibition was abandoned as monotherapy because of severe thrombocytopenia — platelets depend on BCL-XL for survival. AbbVie's TRANSFORM-2 trial revisits navitoclax in myelofibrosis, combining it with ruxolitinib in patients who have relapsed or are refractory to JAK inhibition.

The rationale in myelofibrosis: MF progenitor cells and megakaryocytes overexpress BCL-XL, making them susceptible to navitoclax while JAK2-mutant clones may require BCL-XL co-targeting alongside JAK inhibition for deep responses. TRANSFORM-2 data may reopen the BCL-XL therapeutic window — with important implications for combination strategies in other BCL-XL-dependent malignancies.

Venetoclax + Azacitidine in AML: The Expansion Frontier

The ven+aza standard has become a combination backbone for an entire generation of AML trials. Virtually every new AML drug is entering Phase 3 as an addition to ven+aza rather than as a standalone agent:

Bleximenib (menin inhibitor, Janssen) + ven+aza: NCT06852222 — targeting NPM1-mutant and KMT2A-rearranged AML on top of the ven+aza backbone
Quizartinib (FLT3 inhibitor) + ven+aza: VENP-A-QUI (NCT07478991) — testing FLT3i addition for FLT3-ITD+ AML patients
Oral azacitidine formulations + venetoclax: AZTOUND (NCT04256317, Taiho) — testing oral cedazuridine/azacitidine combination with venetoclax for outpatient administration

For pharma BD, this landscape means: the question is no longer whether venetoclax works in AML, but which combination with venetoclax is optimal for which genetic subtype. Monitoring ven+aza combination trials by molecular target is the critical intelligence task.

Related Drug Class Pages

Monitor BCL-2 Trials Daily — Free

Get alerts when CELESTIAL enrollment milestones are posted, new venetoclax combinations register, or Phase 3 readout dates are announced. Track by drug name or indication.

Start Free Trial →

Frequently Asked Questions

What is the mechanism of action of BCL-2 inhibitors?

BCL-2 (B-cell lymphoma 2) is an anti-apoptotic protein that cancer cells overexpress to avoid programmed cell death. BCL-2 inhibitors like venetoclax displace pro-apoptotic BH3-only proteins (BIM, PUMA, NOXA) from BCL-2, freeing them to activate BAX/BAK, which permeabilizes the mitochondrial outer membrane and triggers apoptosis. This mechanism is distinct from chemotherapy and immune checkpoint inhibition, making BCL-2 inhibitors effective in CLL and AML cell populations resistant to other treatments.

What is tumor lysis syndrome (TLS) risk with BCL-2 inhibitors?

Venetoclax carries a boxed warning for tumor lysis syndrome, particularly in CLL. The risk is highest in patients with high tumor burden (large lymph nodes, high WBC). The mitigation strategy — mandatory 5-week ramp-up dosing from 20mg to 400mg — was developed during the venetoclax clinical program and is required in all indications. Sonrotoclax trials will be watched closely for whether higher BCL-2 potency requires additional TLS precautions.

How does resistance to venetoclax develop?

Venetoclax resistance in CLL occurs through several mechanisms: BCL-2 mutations (particularly G101V, which reduces venetoclax binding affinity), upregulation of alternative anti-apoptotic proteins (BCL-XL, MCL-1), and clonal evolution selecting for TP53-mutant subclones. In AML, venetoclax resistance often involves selection for cells dependent on MCL-1 rather than BCL-2. Understanding resistance mechanisms is critical for designing effective second-line regimens and sequencing strategies.

BCL-2 Inhibitor Clinical Trial Tracker